Elevance Health, Inc.

XNYSHealth care

Last traded price · USD

$417.02

+0.79%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:20 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $413.75
Volume: 2,032
Day's high: —
Day's low: —

In brief

Elevance Health, Inc. is a health care company listed on the New York Stock Exchange, valued at about $90.44B.
Its shares closed at $413.75 on 3 Nov 2026, up 32.1% over the past year.
From India you can buy ELV in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Elevance Health, Inc. (ELV) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ELV share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ELV options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +4.9% (SPY −2.6%, XLV +9.9%). 3 months: +9.5% (SPY −2.2%, XLV +13.5%). 1 year: +32.1% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ELV, SPY and XLV · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $413.75 was 0.7% above its 50-day average ($411.05) and 11.0% above its 200-day average ($372.70). It has closed above the 200-day for 137 sessions, since 21 Apr 2026. The 50-day average crossed above the 200-day on 20 May 2026, 115 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
P/E 24.0% below its peers' median
Trailing P/E of 17.7 against a median of 23.3 across 3 peers named in its company record (range 23.2 to 26.0).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026
Next ex-dividend date: 4 Dec 2026
$1.72 a share, payable 18 Dec 2026; unchanged from the previous payment (ex-date 10 Sep 2026).
Corporate actions record · as of 4 Nov 2026
79% of the way up its 52-week range
Closed at $413.75 on 3 Nov 2026: 8.2% below the 52-week high of $450.69 (21 Oct 2026) and 50.5% above the low of $274.84 (9 Mar 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+4.9%

6 months+12.1%

1 year+32.1%

5 years−2.6%

Newswire

About

Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

Website

Notable moves

January 27, 2026
−14.33%
July 17, 2025
−12.22%
July 2, 2025
−11.50%

Newswire

About

Website

Notable moves

January 27, 2026
−14.33%
July 17, 2025
−12.22%
July 2, 2025
−11.50%

Elevance Health, Inc.

XNYSHealth care

Last traded price · USD

$417.02

+0.79%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:20 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $413.75
Volume: 2,032
Day's high: —
Day's low: —

In brief

Elevance Health, Inc. is a health care company listed on the New York Stock Exchange, valued at about $90.44B.
Its shares closed at $413.75 on 3 Nov 2026, up 32.1% over the past year.
From India you can buy ELV in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Elevance Health, Inc. (ELV) shares from India?

Do I need the price of a whole ELV share to invest?

How much can I invest in US stocks in a year?

Can I trade ELV options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +4.9% (SPY −2.6%, XLV +9.9%). 3 months: +9.5% (SPY −2.2%, XLV +13.5%). 1 year: +32.1% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ELV, SPY and XLV · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $413.75 was 0.7% above its 50-day average ($411.05) and 11.0% above its 200-day average ($372.70). It has closed above the 200-day for 137 sessions, since 21 Apr 2026. The 50-day average crossed above the 200-day on 20 May 2026, 115 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
P/E 24.0% below its peers' median
Trailing P/E of 17.7 against a median of 23.3 across 3 peers named in its company record (range 23.2 to 26.0).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026
Next ex-dividend date: 4 Dec 2026
$1.72 a share, payable 18 Dec 2026; unchanged from the previous payment (ex-date 10 Sep 2026).
Corporate actions record · as of 4 Nov 2026
79% of the way up its 52-week range
Closed at $413.75 on 3 Nov 2026: 8.2% below the 52-week high of $450.69 (21 Oct 2026) and 50.5% above the low of $274.84 (9 Mar 2026).
Daily price bars, split-adjusted · as of 3 Nov 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+4.9%

6 months+12.1%

1 year+32.1%

5 years−2.6%

Newswire

About

Website

Notable moves

January 27, 2026
−14.33%
July 17, 2025
−12.22%
July 2, 2025
−11.50%

Newswire

About

Website

Notable moves

January 27, 2026
−14.33%
July 17, 2025
−12.22%
July 2, 2025
−11.50%

Elevance Health, Inc.

Elevance Health, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

P/E 24.0% below its peers' median

Next ex-dividend date: 4 Dec 2026

79% of the way up its 52-week range

Elevance Health, Inc.

Elevance Health, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

P/E 24.0% below its peers' median

Next ex-dividend date: 4 Dec 2026

79% of the way up its 52-week range